Paula Deen Announces Type 2 Diabetes Diagnosis and Partners Up with Novo Nordisk
Paula Deen Announces Type 2 Diabetes Diagnosis and Partners Up with Novo Nordisk
Shares
After days of rumors regarding Paula Deen’s diabetes diagnosis, the woman dubbed the Queen of Southern Cuisine has announced that she and her sons have partnered up with Novo Nordisk to launch Diabetes in a New Light™, a national initiative to help adults find simple ways to manage everyday challenges associated with type 2 diabetes. As part of the launch Paula Deen is sharing sharing her personal diabetes story for the first time including the fact that she is being treated with Novo Nordisk’s type 2 diabetes drug Victoza.
Diabetes in a New Light™ was developed to help the millions of Americans living with type 2 diabetes tackle some of the most common challenges associated with diabetes management. Resources will include how to prepare diabetes-friendly food without compromising taste, incorporating physical activity into everyday life, managing stress and working with your doctor to find a treatment plan that works for you. Through the program, the Paula Deen and her sons, Bobby and Jamie Deen, are creating modified, diabetes-friendly versions of their favorite recipes and appearing at diabetes cooking events across the country.
People can visit the program’s website, www.DiabetesinaNewLight.com, to learn more about Paula’s story, get diabetes-friendly recipes, as well as tips and information about type 2 diabetes management.
Medtronic Announces Initiatives to Address Health Equity for… Medtronic has announced its ongoing commitment to health equity for people of color living with diabetes. The company committed investments in partnerships with the American Diabetes Association® (ADA) and T1D Exchange,…
Type 2 Diabetes and COVID-19: What We Know Now Our early understanding of the novel coronavirus, and the CDC recommendations that have largely driven American policy and behavior, were based almost entirely on the first reports to trickle out…
The Latest Numbers on COVID-19 and Type 1 Diabetes In late May, we wrote about the first studies to explicitly analyze the health outcomes of people with Type 1 diabetes during the coronavirus pandemic. At the time, the two…
Insulin Treatment is Associated with Increased Mortality in… A new study in Cell Metabolism has suggested that patients with COVID-19 and Type 2 diabetes that received insulin treatments were significantly more likely to die than those that did…
We use cookies to optimize our website and our service.
Functional cookies Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.